Selection of isatuximab dosing regimen in pediatric patients with leukemia using population pharmacokinetics
The modeling and simulation strategies in this study support the previous selection of a 20-mg/kg dose for all age groups and enabled both de-risking of dose selection and the ability to pursue additional pediatric investigation of isatuximab in the youngest age group of patients with acute leukemias.
Authors
- André Baruchel (ORCID: https://orcid.org/0000-0003-0120-6089)
- C. Michel Zwaan (ORCID: https://orcid.org/0000-0001-6892-8268)
- Claire Brillac (ORCID: https://orcid.org/0000-0002-1743-3211)
- Corina Oprea
- Laurent Nguyen (ORCID: https://orcid.org/0000-0002-8560-3008)
- Dorothée Sémiond
Institutions
- Université Paris Cité (FR)
- Sanofi (France) (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Sanofi (United States) (US)
- Hôpital Robert-Debré (FR)
- Princess Máxima Center (NL)
- Erasmus MC - Sophia Children’s Hospital (NL)
Publication Details
- Journal
- Cancer Chemotherapy and Pharmacology
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1007/s00280-025-04832-2
- Primary Topic
- Acute Lymphoblastic Leukemia research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Sanofi